Tridek-One, Paris, Octobre 2, 2019 –The biotech strengthens its executive team
Tridek One, a French biotechnology company specializing in the development of products for the treatment of immune and inflammatory disorders, today announced the strengthening of its management team with the appointments of Regis Olivier to the position of Chief Financial Officer, Dr Jorge Kirilovsky as Chief Scientific Officer and Dr Delphine Joyeux as Chief Development Officer. Delphine, Régis, and Jorge join the Executive Committee of the company.
“We are proud to welcome Delphine, Regis and Jorge to Tridek-One. We count on them so that their very rich experience contributes to the development of our product portfolio. As members of the Executive Committee of the company, they join a very talented scientific and clinical team totally dedicated to the discovery of innovative products for the treatment of immune disorders, including inflammatory pathologies, “says Philippe Berthon, Chief Executive officer, Tridek-One.
Mr. Regis Olivier (54) joined Tridek-One as Chief Financial Officer. He brings more than 25 years of experience in finance and business management of healthtech companies. Prior to joining Tridek-One, Regis was CEO of Axess Vision Technology (2014-2019), a company dedicated to the development of single-use medical endoscopes, where he led the launch of new products and successfully completed its refinancing. Previously (2008-2014), he was Chief Financial Officer of Echosens, a medical technology company specializing in the non-invasive detection of liver diseases, for which he led the restructuring and divestment in 2011. Earlier on, he held several financial analyst and management controller positions in the industrial sector. Mr. Olivier holds a Master’s degree in Finance and Management from EDC Paris.
Dr. Jorge Kirilovsky (63) joined Tridek-One as Chief Scientific Officer. Jorge is internationally recognized as an expert in drug discovery. Former Vice President and General Manager of the GSK Research Center in France (1998 – 2018), Jorge led a group of more than 100 biologists, chemists, pharmacologists and clinicians working together to identify new drug candidates for development. The discovery of tadalafil (Cialis™) for the treatment of erectile dysfunction and of the first epigenetic candidate drug to reach clinical development are among his main contributions. Dr. Kirilovsky also participated in the identification and selection of about 20 drug candidates in the areas of immuno-inflammation, cardiovascular disease and oncology. Jorge is currently a member of the BPI Large Ventures Health Expert Committee, the SATT Paris-Saclay Investment Committee and the Medicen-Paris Project Evaluation Committee. Jorge Kirilovsky received his Ph.D. in biochemistry from the Hebrew University of Jerusalem before a postdoc in molecular neurobiology at the Institut Pasteur in Paris.
Dr. Delphine Joyeux (47) has joined Tridek-One as Chief Development Officer. During her career, Delphine has established herself as an expert in pharmaceutical product development and regulatory affairs in both Europe and the United States. She has contributed to the filing and approval of numerous clinical trial authorization (IND), as well as new drug applications in Europe (EMA) and the United States (FDA), including Loramyc™, Sitavig™, Pretherax™. Prior to joining Tridek-One, Dr. Joyeux was Chief Operating Officer at Minka Therapeutics (2013-2019). Previously, Delphine held various positions related to regulatory affairs and product development at Onxeo in France (2006-2013), Agouron-Pfizer in the United States (2000-2006) and Servier in France (1997-2000). Delphine Joyeux is a doctor in Pharmacy from Paris-Saclay University and holds a Master in International Development and Registration of Medicinal Products.
Founded in 2018 by Dr Giuseppina Caligiuri and Professor Antonino Nicoletti, researchers in the INSERM 1148 Unit located at the Bichat Hospital in Paris, together with the Advent France Biotechnology Fund (Dr Alain Huriez), Tridek-One offers a CD31 agonist approach for immune modulation. This is a novel mode of action to treat many inflammatory pathologies in therapeutic stalemate. Two therapeutic classes are currently being developed, monoclonal antibodies activating CD31, and CD31 agonist peptides. Tridek-One announced in June 2019 funding of 3 million euros by Advent France Biotechnology and Advent Life Sciences (UK). For more information, visit Tridek One Website and join Twitter: @TridekOne
Press Contacts ALIZE RP:
Caroline Carmagnol et Aurore Gangloff
email@example.com – +33 6 64 18 99 59
firstname.lastname@example.org – + 33 6 49 57 82 68
email@example.com – +01 60 87 89 32
Website : www.tridekone.com
Twitter : @TridekOne